Bioscience – MJ Shareholders https://mjshareholders.com The Ultimate Marijuana Business Directory Wed, 01 Mar 2023 19:55:04 +0000 en-US hourly 1 https://wordpress.org/?v=6.5.5 Hill Street Announces Record Revenues and Gross Profit as Strong Growth Continues https://mjshareholders.com/hill-street-announces-record-revenues-and-gross-profit-as-strong-growth-continues/ Wed, 01 Mar 2023 19:55:04 +0000 https://cannabisfn.com/?p=2972746

Ryan Allway

March 1st, 2023

News, Top News


Toronto, ON – TheNewswire – March 1, 2023 – Hill Street Beverage Company Inc. (TSXV:HILL) (OTC:HSEEF) (“Hill Street” or the “Company”), a progressive bioscience implementation company that utilizes new technologies to provide innovative cannabis solutions and non-alcoholic beverage products globally, is pleased to announce the following updates from the three-month period ended December 31, 2022 (“Q2 FY 2023”) financial statements.

Continued DehydraTECH™ Expansions Lead to Record Quarterly Licensing Revenue & Growth

The Company continued to add states to its geographic footprint for DehydraTECH™ licensing as well as form factors to its portfolio of DehydraTECH™-powered consumer products during the three-month period ended December 31, 2022.

As a result, the Company is pleased to announce that it grew DehydraTECH™ licensing revenues by 93% in Q2 versus the prior quarter and 263% for the fiscal year to date.

The following chart shows the DehydraTECH™ licensing revenues over the past 6 quarters:

In 000’s Dec 31, 2022 Sept. 30,  2022 June 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021
Licensing Revenue 328 170 138 77 59 130

The Transformed Vin(Zero) Business Model Leads to Record High Quarterly Revenue and Gross Profit

In Q2 FY 2023, Hill Street achieved record quarterly revenues overall and also for its Vin(Zero) alcohol-free beverage business.  The Vin(Zero) results were primarily driven by the Company’s new streamlined Vin(Zero) business model that created a new and different cadence to that business, as we have previously announced.   The Company now executes larger orders that are spread months apart to optimize the timing and efficiency of our supply chain.  The new business model significantly improves key financial metrics such as order to cash and reduced working capital in inventory, but the Vin(Zero) business must now be looked at across longer time frames to truly understand its patterns.

The following chart shows the Vin(Zero) alcohol-free business results over the past 6 quarters:

In 000’s Dec 31, 2022 Sept. 30, 2022 June 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021
Gross Revenue 1,487 188 1,198 778 476 527
Chargebacks (249) (27) (217) (108) (68) (56)
Net Revenue 1,238 161 981 670 408 471
CoGS (738) (113) (747) (406) (252) (270)
Gross Profit 500 48 234 264 156 201
GP % 34% 26% 20% 34% 33% 39%

Release of Q2 FY2023 Financial Statements and MD&A

For the three-month period ended December 31, 2022, the Company has released its Financial Statements, and a comprehensive Company update by way of its Management Discussion and Analysis, which can now be found on the Company’s profile at www.sedar.com.

Craig Binkley, CEO comments: “This was by far the best quarterly result in the Company’s history, for both business units. We are very pleased that our December 31, 2022 results for the Vin(Zero) business validate that the fundamental adjustments we made to our business model over the past several months were well considered and on target.  By refocusing our efforts towards our two on-trend, strong-margin and streamlined business segments – Vin(Zero) beverage sales and DehydraTECH™ licensing – we are well positioned as we head into the spring.”

Hill Street Mailing List Launched

With the Company expecting increasing shareholder communication over the coming months, Hill Street is pleased to also announce that it has initiated an exclusive mailing list for all supporters wishing to receive direct and timely communication about Company updates.  If you wish to sign up for this mailing list, click HERE.

*All financial information is provided in Canadian dollars, is unaudited and subject to change.

About Hill Street Beverage Company Inc. (TSXV: HILL)

Hill Street is a progressive bioscience implementation company that utilizes new technologies to provide innovative cannabis solutions and non-alcoholic beverage products globally. We are pioneering the space where craft consumer products meet bioscience by leveraging our deep CPG expertise to commercialize leading-edge technologies to craft superior plant-derived consumer products. We are currently developing the platform for North American distribution around our rights to use Lexaria Bioscience Corp.’s ground-breaking DehydraTECH™ patent portfolio for product development, licensing and B2B sales of cannabis ingredients.

For more information on our business activities or to check out Hill Street’s award-winning alcohol-free line-up and order product to be delivered straight to your home go to www.hillstreetbeverages.com

For more information:

Matthew Jewell, Chief Financial Officer
matthew@hillstreetbevco.com

FORWARD-LOOKING STATEMENTS

Statements in this press release may contain forward-looking information. Any statements in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “would”, “anticipate”, “expects”, and similar expressions. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances, such as future availability of capital on favourable terms, may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this press release are expressly qualified by this cautionary statement. The forward-looking statements contained in this press release are made as of the date of this press release. The Company does not undertake any obligation to update publicly or to revise any of the included forward-looking statements, whether as a result of new information, future events or otherwise, except as required by securities law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Emerald Health Therapeutics and Skye Bioscience Announce Intended Closing Date of Plan of Arrangement https://mjshareholders.com/emerald-health-therapeutics-and-skye-bioscience-announce-intended-closing-date-of-plan-of-arrangement/ Mon, 07 Nov 2022 16:46:49 +0000 https://www.cannabisfn.com/?p=2968108

Skye will continue to pursue Canadian Securities Exchange listing following closing of transaction targeting glaucoma

VANCOUVER, BC, November 7, 2022– Emerald Health Therapeutics, Inc. (“Emerald” or the “Company”) (CSE: EMH; OTCQB: EMHTF) and Skye Bioscience, Inc. (“Skye”) (OTCQB: SKYE) announced today that they intend to close the previously announced Plan of Arrangement (“Arrangement”) on or about November 10, 2022, and that they waived the condition that Skye obtain a conditional approval to list its shares on the Canadian Securities Exchange (“CSE”) prior to closing the Arrangement.

After careful consideration, each of the Company and Skye determined that closing the transaction at this time was in their mutual best interest. The closing of the Arrangement will, among other things, result in the Company’s shareholders receiving their shares of Skye under the Arrangement and will allow the Company to complete the sale of its remaining cannabis assets and create funds to be utilized in Skye’s Phase 1 clinical trial, which is expected to begin before the end of 2022. Although the conditional listing requirement has been waived, Skye has covenanted that it will use its best efforts to obtain the listing of its shares on the CSE as soon as possible. The Skye listing application was submitted to the CSE on August 31, 2022 and is currently under review.

Emerald recommends that shareholders holding their shares in registered accounts seek tax advice prior to the closing of the Arrangement with respect to the tax consequences of the Arrangement closing prior to the listing of Skye’s shares on the CSE.

CONTACT
Investor Relations
Email:[email protected]  
Phone: (858) 410-0266

FORWARD-LOOKING STATEMENTS

This letter contains forward-looking statements, including statements regarding our product development, business strategy, the timing of clinical trials, and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye’s most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.

]]>
Skye Bioscience Files Definitive Proxy Statement and Announces Stockholder Meeting Date https://mjshareholders.com/skye-bioscience-files-definitive-proxy-statement-and-announces-stockholder-meeting-date/ Thu, 01 Sep 2022 17:25:38 +0000 https://www.cannabisfn.com/?p=2960486

Ryan Allway

September 1st, 2022

News, Top News


San Diego, California, Sept. 01, 2022 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, announces that it has filed its definitive proxy statement related to its special meeting to be held online on September 30, 2022.

Stockholders as of August 29th, 2022, will receive a definitive proxy statement, voting card, and voting instructions by mail or email. The definitive proxy statement includes all pertinent information related to, among other matters, the proposed business combination between Skye and Emerald Health Therapeutics, Inc. (“Emerald”). Skye’s special meeting will take place via live audio webcast at https://web.viewproxy.com/skye/2022 on September 30, 2022 at 9:00 a.m. (Pacific time).

YOUR VOTE IS IMPORTANT. After you receive the proxy and voting materials, please review them carefully and do promptly vote your shares. You will have the ability to vote in advance of the meeting after you receive your proxy materials. Whether or not you expect to attend the Skye meeting virtually, please submit your vote as soon as possible.

“We are grateful for the support of Emerald’s leadership and greatly appreciate that Emerald shareholders voted in favor of the proposed business combination between our two companies,” said Punit Dhillon, CEO and Chair. “We now look forward to completing the Skye stockholder voting process. Completing this transaction would provide us with valuable resources to execute our business plan. The votes of all stockholders, small and large, do count. We invite and strongly encourage you to take the time to support your Company with your positive vote, as per the recommendation of Skye’s Board of Directors.”

The definitive proxy statement can be viewed at https://ir.skyebioscience.com/sec-filings/all-sec-filings.

About Skye Bioscience
Skye Bioscience is a pharmaceutical company unlocking the potential of cannabinoids through the development of its proprietary cannabinoid derivatives to treat diseases with significant unmet needs. The company’s lead program, SBI-100 OE, is focused on developing a treatment for glaucoma, the world’s leading cause of irreversible blindness. For more information, please visit: www.skyebioscience.com.

CONTACT
Investor Relations
Email: [email protected]
Phone: (858) 410-0266

Additional Information and Where to Find It
In connection with the proposed business transaction, Skye has filed a proxy statement on Schedule 14A containing important information about the proposed transaction and related matters and may file other relevant documents with the SEC regarding the proposed transaction. Investors of Skye are urged to carefully read the entire proxy statement (including any amendments or supplements to such documents), respectively, when such documents become available before making any voting decision with respect to the proposed transaction because they will contain important information about the proposed transaction and the parties to the transaction.

Investors and security holders of Skye will be able to obtain a free copy of the proxy statement, as well as other relevant filings containing information about Skye and the proposed transaction, including materials that will be incorporated by reference into the proxy statement, without charge, at the SEC’s website (www.sec.gov) or from Skye by contacting Skye’s Investor Relations at (858) 410-0266, by email at [email protected], or by going to Skye’s Investor Relations page on its website at https:/ir.skyebioscience.com and clicking on the link titled “SEC Filings.”

Participants in the Solicitation
Skye and certain of its respective directors, executive officers and employees may be deemed to be participants in the solicitation of Skye proxies in respect of the proposed transaction. Information regarding the persons who may, under SEC rules, be deemed participants in the solicitation of proxies to Skye stockholders in connection with the proposed transaction will be set forth in the Skye proxy statement for the proposed transaction when available. Other information regarding the participants in the Skye proxy solicitation and a description of their direct and indirect interests in the proposed transaction, by security holdings or otherwise, will be contained in such proxy statement and other relevant materials to be filed with the SEC in connection with the proposed transaction. Copies of these documents may be obtained, free of charge, from the SEC or Skye as described in the preceding paragraph.

FORWARD LOOKING STATEMENTS
This letter contains forward-looking statements, including statements regarding our product development, business strategy, the timing of clinical trials, and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye’s most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Skye Bioscience Receives Australian Ethics Committee Approval to Start First-in-Human Phase 1 Study of SBI-100 Ophthalmic Emulsion https://mjshareholders.com/skye-bioscience-receives-australian-ethics-committee-approval-to-start-first-in-human-phase-1-study-of-sbi-100-ophthalmic-emulsion/ Thu, 30 Jun 2022 17:31:49 +0000 https://www.cannabisfn.com/?p=2954012

Ryan Allway

June 30th, 2022

News, Top News


Lead drug candidate has shown superior and longer-lasting lowering of intraocular pressure, a risk factor associated with glaucoma, in preclinical studies

San Diego, California–(Newsfile Corp. – June 30, 2022) – Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has received regulatory approval to begin its first-in-human Phase 1 clinical study of SBI-100 Ophthalmic Emulsion (“SBI-100 OE”) from the Australian Human Research Ethics Committee (“HREC”). SBI-100 OE is a patented drug representing a new class of therapeutics to potentially treat glaucoma.

The primary endpoints for this randomized, double-masked, placebo-controlled Phase 1 study of SBI-100 OE are an assessment of safety and tolerability of the drug in healthy volunteers. The secondary endpoint is an assessment of pharmacokinetics. The study will also measure changes to intraocular pressure. A total of 48 subjects will be administered SBI-100 OE or placebo in single ascending dose (SAD) and multiple ascending dose (MAD) arms. Preliminary top-line data is expected in Q4 and final data in Q1 of 2023.

In the study, each arm will consist of three cohorts of eight subjects, six receiving SBI-100 OE and two receiving placebo. In the SAD arm, each subject will be administered a single 35uL drop to one study eye of placebo or SBI-100 OE at concentrations of 0.5%, 1.0% and 2.0% of active drug in cohorts one, two, and three, respectively. In the MAD arm, each subject will receive two drops per day over five days using the respective dose levels of the SAD arm. A Safety Review Committee will monitor the study and review safety data before approving escalation to the next cohort.

“After submitting our clinical trial protocol to HREC in March, we are pleased to receive their approval and look forward to assessing SBI-100 Ophthalmic Emulsion for the first time in humans,” said Tu Diep, Chief Development Officer of Skye. “Decades of research have established the role of cannabinoid receptor type 1 (CB1R) in lowering IOP, however, there has been no CB1R agonist therapeutic agent approved by a regulatory agency to treat glaucoma. No other company has methodically created a patented molecule and proprietary formulation – representing a new class of therapeutic drug – to improve the inherent positive attributes of natural cannabinoids while limiting potentially negative systemic effects, and with the goal of enhancing the treatment of glaucoma beyond today’s approved drugs.

“Achieving these goals is Skye’s focus. We have not only created a drug with this ambition but we have also navigated the complexities of synthetic manufacturing and conducted extensive preclinical assessments, and now we are embracing the rigors of the clinical and regulatory processes to validate our drug.”

The Phase 1 study will be conducted in the clinical trial facility of CMAX Clinical Research in Adelaide, Australia (“CMAX”). Conducting the Phase 1 clinical study in Australia qualifies Skye to receive a tax credit of up to 43.5%.

Next Steps

  • Submission of Clinical Trial Notification to Australian Therapeutic Goods Administration. This submission is prepared and will be filed now that HREC approval has been obtained.
  • Site visit and training. Skye will train the study investigators and CMAX’s clinical study staff on the clinical protocol and procedures and ensure that the pharmacy understands how to appropriately handle the drug formulation.
  • Clinical trial material (CTM) production. The manufacturing process of SBI-100 OE requires very specific and specialized equipment, consumables and excipients that cannot be easily substituted. Global supply chain constraints delayed or limited access to certain components of the manufacturing process and delayed CTM production, which was originally scheduled to be completed in early June. We are working with our contract manufacturer, Pharmaceutics International Inc., to finalize logistical and scheduling details. We expect to complete Phase 1 CTM production in July.
  • Secure DEA export license and deliver CTM to Australia. Skye has secured the import license required for a controlled substance from the Australian Department of Health. We require an export license from the U.S. Drug Enforcement Agency but must complete CTM production before submitting our application. There can be variability in the timing of the DEA’s review and issue of an export license. We do not expect to receive this license earlier than August, after which delivery of drug product to Australia will be expedited.
  • Subject screening, enrollment, and first dosing. Recruitment of study participants will begin after the prior listed steps are substantially completed, since subjects must be administered drug within 28 days of enrollment. Taking into account the listed variables, Skye is aiming to dose the first subject in August.
  • Reporting of study data. Skye expects to report preliminary topline data in Q4 2022, with final data to be reported in Q1 2023.

“Glaucoma is still an inadequately treated disease that has lacked pharmacological innovation for decades. There is a need for new classes of therapeutics with differentiated mechanisms of action and we have strong conviction in the potential of our novel drug based on relevant independent research and our preclinical data,” said Punit Dhillon, CEO and Chair of Skye. “This study will be the first time a novel cannabinoid prodrug will be topically delivered into human’s eyes using a nanoemulsion formulation, and marks an important step in the development of SBI-100 Ophthalmic Emulsion to demonstrate the safety of this approach. Importantly, this study may also provide initial insights into this drug’s effect on IOP.

“In parallel, we aim to submit an investigational new drug (IND) application, which is not dependent upon Phase 1 data, with the FDA by year-end for our planned US-based Phase 2 in 2023 to assess efficacy and safety in patients with glaucoma.”

About SBI-100 Ophthalmic Emulsion
Increased intraocular pressure (IOP) is a key risk factor in the progression of glaucoma. The first observations that consuming cannabis lowered IOP in humans took place in the early 1970s, which led to a significant amount of research on the effects of cannabinoids in the eye. Independent studies demonstrated that activation of the cannabinoid receptor-type 1 (CB1R) in ocular tissue mediates IOP-lowering. However, no cannabinoid-related drug has been approved for clinical use in the eye due primarily to the shortcomings of current delivery methods of CB1R agonists to the eye in a therapeutically beneficial dose. When cannabinoids are administered systemically they can lower IOP but also result in undesirable psychotropic effects. Alternatively, extracted natural cannabinoids delivered topically as an eye drop do not penetrate ocular tissue well enough to effectively lower IOP due to the lipophilic, or oily, properties of natural cannabinoids and the aqueous, or watery, surface of the eye.

To address these challenges, Skye developed SBI-100 OE, a proprietary, synthetic cannabinoid derivative possessing a novel molecular structure and formulation that was rationally designed to enable better penetration of ocular tissue and effective topical delivery of a CB1R agonist. In preclinical studies involving three different species, a nanoemulsion formulation of the drug applied topically to the eye resulted in enhanced therapeutic efficacy and duration of response in lowering IOP. Importantly these studies also demonstrated advantages compared to today’s standard of care and, if clinically validated in subsequent efficacy studies, may provide a suitable therapeutic window to be a new class of medicine for glaucoma.

About Skye Bioscience
Skye Bioscience is a pharmaceutical company unlocking the potential of cannabinoids through the development of its proprietary cannabinoid derivatives to treat diseases with significant unmet needs. The company’s lead program, SBI-100 OE, is focused on developing a treatment for glaucoma, the world’s leading cause of irreversible blindness. For more information, please visit: www.skyebioscience.com.

CONTACT
Investor Relations
Email: [email protected]
Phone: (858) 410-0266

FORWARD-LOOKING STATEMENTS
This letter contains forward-looking statements, including statements regarding our product development, business strategy, the timing of clinical trials, and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye’s most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Artelo Biosciences Presents Positive Pre-Clinical Results of ART26.12, a Novel FABP5 Inhibitor, in Alleviating Chemotherapy-Induced Pain https://mjshareholders.com/artelo-biosciences-presents-positive-pre-clinical-results-of-art26-12-a-novel-fabp5-inhibitor-in-alleviating-chemotherapy-induced-pain/ Mon, 27 Jun 2022 17:03:23 +0000 https://www.cannabisfn.com/?p=2953405

Ryan Allway

June 27th, 2022

News, Top News


Presentation delivered by Professor Saoirse O’Sullivan at the 32nd Annual ICRS Symposium in Galway, Ireland on Sunday, June 26th

SOLANA BEACH, Calif., June 27, 2022 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, announced that Professor Saoirse O’Sullivan, Vice President of Translational Sciences at Artelo Biosciences, presented new research results entitled, “Discovery and Preclinical Evaluation of a Novel Inhibitor of FABP5, ART26.12, Effective In Chemotherapy-Induced Pain,” during the opening oral session of the International Cannabinoid Research Society (ICRS) Symposium.

“Our pre-clinical research showed that chronic, oral treatment with ART26.12, our lead FABP5 inhibitor, was effective at both preventing and treating both oxaliplatin and paclitaxel-induced pain sensitivity without any sedating effects,” said Professor Saoirse O’Sullivan. “In the prevention studies, ART26.12 also minimized the acute weight loss caused by oxaliplatin. These results support further development of ART26.12 in neuropathy associated with chemotherapy and other neuropathies,” continued Professor O’Sullivan.

Chemotherapy-Induced Peripheral Neuropathy, also known as CIPN, is a common and often painfully debilitating complication of cancer therapies, sometimes resulting in reduction or cessation of treatment. For some cancer patients, CIPN may persist long after chemotherapy is stopped. In pre-clinical models of CIPN, inhibition of fatty acid binding protein 5 (FABP5) has demonstrated positive activity in analgesia, ameliorating effects of CIPN, a condition for which no currently approved treatment exists.

“Development of therapeutics for CIPN represents an attractive, new opportunity for Artelo’s FABP5 inhibitors,” said Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “While we continue to develop our inhibitors to FABPs in cancer and anxiety, based on these latest research findings in CIPN, we intend to meet with the FDA for pre-IND consultation on ART26.12 before the end of this year.”

The ICRS Symposium is being held at the Bailey Allen Hall at the National University of Ireland, Galway, from June 25-30, 2022.

About ART26.12
Fatty Acid Binding Proteins (FABPs) are a family of intracellular proteins that chaperone lipids including endocannabinoids and fatty acids. Various inhibitors of FABPs may be particularly useful for the treatment of specific cancers, neuropathic and nociceptive pain, and anxiety disorders. ART26.12, Artelo’s lead FABP inhibitor compound, is a selective inhibitor of FABP5. While developing our lead molecule for Chemotherapy-Induced Peripheral Neuropathy, additional compound(s) from our extensive library of potent and selective inhibitors of FABPs have been identified and selected for advancement towards regulatory-enabling studies in cancer and other areas of high-unmet need where inhibition of FABPs show significant promise.

About Artelo Biosciences
Artelo Biosciences, Inc. is a clinical stage pharmaceutical company dedicated to the development and commercialization of proprietary therapeutics that modulate lipid-signaling pathways including the endocannabinoid system. Artelo is advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, anxiety, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at www.artelobio.com and Twitter: @ArteloBio.

About the International Cannabinoid Research Society
The International Cannabinoid Research Society (ICRS) is the premier global scientific association with more than 650 international members from 40 countries, all active researchers in the field of endogenous, plant-derived, and synthetic cannabinoids and related bioactive lipids. In addition to acting as a source for impartial information on cannabis and the cannabinoids, the main role of the ICRS is to provide an open forum for researchers to meet and discuss their research. Interested parties may follow @ICRS_Society and @sciencesaoirse on Twitter and use #ICRS2022 for the latest meeting updates.

Forward Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission, including our ability to raise additional capital in the future. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise, except to the extent required by applicable securities laws.

Investor Relations Contact:
Crescendo Communications, LLC
Tel: 212-671-1020
Email: [email protected]

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Isracann Biosciences Signs Definitive Agreement to Acquire Natural Health Medicine Developer https://mjshareholders.com/isracann-biosciences-signs-definitive-agreement-to-acquire-natural-health-medicine-developer/ Mon, 28 Mar 2022 16:10:43 +0000 https://www.cannabisfn.com/?p=2942105

Ryan Allway

March 28th, 2022

News, Top News


VANCOUVER, British Columbia, March 28, 2022 (GLOBE NEWSWIRE) — Isracann Biosciences Inc. (CSE: IPOT) (XFRA: A2PT0E) (OTC: ISCNF) (the “Company”) is pleased to announce that, further to the Company’s news release dated February 23, 2022, it has entered into a definitive agreement (the “Agreement”) dated March 24, 2022 with Praesidio Health Inc. (“Praesidio”). Pursuant to the Agreement, the Company will acquire all of the issued and outstanding shares in the capital of Praesidio (the “Praesidio Shares”) for aggregate consideration of C$4,000,000 in common shares (the “Consideration Shares”) of the Company (the “Transaction”). Upon closing of the Transaction (“Closing”), Praesidio will operate as a wholly-owned subsidiary of the Company.

Praesidio Health (https://www.praesidiohealth.com/) is an industry-leading, Canadian medical research company that develops and validates natural health medicine (“NHM”) using an evidence-based process. Pioneering NHMs and therapeutics, Praesidio Health is actively developing several product candidates for utility in a range of conditions, including post-viral exposure prophylaxis, urological, anxiety/stress, immune booster, and sleep aids. The company employs formulation combinations with and without cannabinoids and/or psilocybin, which opens the opportunity for product development in conjunction with future operations in Israel including direct access to European markets.

The Consideration Shares will be issued in seven tranches, with C$1,000,000 of the Consideration Shares being issued at Closing and C$500,000 of the Consideration Shares being issued every six months thereafter until the third anniversary of the date of Closing. The price of the Consideration Shares will be equal to the volume weighted average of actual trading prices (measured in hundredths of cents) of the common shares in the capital of the Company on the Canadian Securities Exchange (the “CSE”) for the ten consecutive business days prior to the applicable date of issuance. The Consideration Shares will be subject to a 48-month contractual escrow period, which will begin on date of Closing.

The Transaction remains subject to certain closing conditions, including, without limitation, the receipt of all necessary corporate and regulatory approvals and other customary closing conditions. There can be no assurance that the Transaction will be completed as proposed or at all. Closing of the Transaction is expected to occur on or about April 4th, 2022.

The securities of the Company referred to in this news release have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or any state securities laws. Accordingly, the securities of the Company may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable state securities laws. This news release does not constitute an offer to sell or a solicitation of any offer to buy any securities of the Company in any jurisdiction in which such offer, solicitation or sale would be unlawful.

About Isracann Biosciences Inc.

Isracann is an Israeli-based cannabis company focused on becoming a premier cannabis producer offering low-cost production targeting undersupplied, major European marketplaces. Based in Israel’s agricultural sector, Isracann will leverage its development within the most experienced country in the world with respect to cannabis research. The Company has secured agreements within Israel for medicinal marijuana cultivation. For more information visit: www.isracann.com.

ON BEHALF OF THE BOARD OF DIRECTORS

“Phil Floucault”

Phil Floucault
Chief Executive Officer and President

The CSE does not accept responsibility for the adequacy or accuracy of this release.

Forward-Looking Information

This release may contain forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words “expects”, “plans”, “anticipates”, “believes”, “intends”, “estimates”, “projects”, “potential” and similar expressions, or that events or conditions “will”, “would”, “may”, “could” or “should” occur. Forward-looking statements may include, without limitation, statements relating to the Transaction and the Consideration Shares. The forward-looking statements contained in this press release are expressly qualified in their entirety by this cautionary statement. All forward-looking statements in this press release are made as of the date of this press release. The forward-looking statements contained herein are also subject generally to assumptions and risks and uncertainties that are described from time to time in the Company’s documents filed from time to time with the CSE, the British Columbia Securities Commission, the Alberta Securities Commission, and the Ontario Securities Commission. Although Isracann believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in forward looking statements. Isracann expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

Contact
Empire Communications Group
+1 (604) 343-2724
[email protected]
www.isracann.com

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Coping With Stress During the COVID-19 Outbreak with CBD & Adaptogens https://mjshareholders.com/coping-with-stress-during-the-covid-19-outbreak-with-cbd-adaptogens/ Mon, 30 Mar 2020 17:05:25 +0000 https://www.cannabisfn.com/?p=2768163

Ryan Allway

March 30th, 2020

Uncategorized


The COVID-19 outbreak has become a major source of stress over the past several weeks. In addition to the fear and anxiety of disease, quarantines and “stay at home” orders have contributed to stress levels, leading to poor sleep, unhealthy eating, and other side-effects. It’s important for everyone to take inventory of their health and take action.

Let’s take a look at some strategies to cope with these heightened stress and anxiety levels, as well as how cannabidiol (CBD) and adaptogens could play a role.

How to Reduce Stress & Anxiety

There are many different ways to cope with the fear and anxiety stemming from the COVID-19 outbreak. While some people already have good routines in place, others may have to build new habits and integrate them into a completely new lifestyle under lockdown. The good news is that there’s plenty of good advice from the experts.

The Centers for Disease Control (CDC) had several recommendations:

  • Take breaks from watching, reading, or listening to news stories, including social media.
  • Eat a healthy, well-balanced diet, exercise regularly (away from others), try to get plenty of sleep and avoid smoking cigarettes, alcohol and drugs.
  • Connect with others remotely using voice calls or video chats and discuss how you’re feeling and any concerns.
  • Take time to yourself and try new activities that you might enjoy.

Other common suggestions include:

  • Practice mindfulness by focusing on the present moment from time to time.
  • Limit access to stressors by refusing non-essential tasks that are stressful and allowing yourself to take breaks.
  • Delegate some responsibilities to others where possible, such as asking children to do the dishes.

While most people have experienced an impact from the crisis, those with pre-existing mental health conditions should be especially cognizant of worsening symptoms. Parents should also monitor the stress levels of children and teens that may experience more intense feelings. Call your healthcare provider if stress gets in the way of your daily activities for several days.

Accredited? Click here to see Innoviom’s deck and learn more about the company’s current offering

CBD & Adaptogens Could Help

There are many different foods and beverages that have a demonstrated ability to promote relaxation and reduced stress levels.

Most people are familiar with the benefits of green tea, chamomile, lavender and lemon balm when it comes to stress reduction. These ingredients are often referred to as adaptogens — or non-toxic plants that help the body resist physical, chemical or biological stressors. Many of them have been used for centuries in Chinese and Ayurvedic healing traditions.

Cannabidiol, or CBD, has also become a popular wellness product over the past several months. In early stage studies, researchers found that CBD may alter serotonin signals that modulate feelings of anxiety and depression. A generalized anxiety disorder study, for instance, showed that CBD reduced stress in animals, such as rats.

Accredited? Click here to see Innoviom’s deck and learn more about the company’s current offering

Innoviom’s goal is to bring these ingredients to consumers through functional beverages. It’s flagship Tranquini® brand is a natural de-stress drink that contains a unique blend of these relaxing adaptogens. Meanwhile, Wowie™ by Tranquini® combines these adaptogens with hemp extract to provide an even greater relaxation effect.

Unlike other companies, Innoviom has taken the research into adaptogens and CBD and turned it into great tasting functional drinks — with a focus on the great tasting part! Tranquini® is distributed through U.S. chains, such as Meijer, and via distributors, such as KeHE and UNFI. Wowie™ is also being rolled out in jurisdictions where sales are permitted.

Follow us on social media:

Looking Ahead

Innoviom is led by CEO Ahmed El Azizi, former Global VP of Functional Beverages at PepsiCo, who has over 20 years of beverage experience. He’s joined by Group CFO Christine Morcos, who came from Pfizer, Gillette and P&G and Chief Growth Officer Julia Trofimova, a former employee of several consumer product companies, including RedBull.

The company’s experienced consumer products team recognized an emerging market opportunity and has the ability to execute on an aggressive growth plan.

Accredited investors interested in learning more about investing in Innoviom can sign up to receive its investor deck and offering details.

Accredited? Click here to see Innoviom’s deck and learn more about the company’s current offering

Statements not evaluated by the FDA.

Innoviom, Inc. Company Contact:

Ahmed Al Azizi CEO

[email protected]

CFN Media Contact:

Frank Lane President

[email protected]

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Israel Begins Cannabis Exports to Meet Unmet Medical Needs https://mjshareholders.com/israel-begins-cannabis-exports-to-meet-unmet-medical-needs/ Wed, 25 Mar 2020 22:37:37 +0000 https://www.cannabisfn.com/?p=2767660

Ryan Allway

March 25th, 2020

App, Exclusive, News, Top Story


Israel has long been an international center for cannabis research. THC, the psychoactive ingredient in cannabis, and CBD, the plant’s predominant non-psychoactive ingredient, were first isolated and defined by Israeli researcher Dr. Raphael Mechoulam in the early 1960s. Research continued there in the following decades, and the Israeli government has contributed greatly to the country’s prominence in the global cannabis industry. 

In Israel, medical cannabis is legal while recreational use remains technically illegal, though the government decriminalized recreational use to some extent in 2017. Government agencies provide funding for cannabis research. In January 2019, the government passed a law to allow exports of medical cannabis, though the first export was announced a year later in January 2020. With that recent development, the table appears set for growth in the Israeli cannabis market. 

Click below to view more on Isracann Biosciences  – Israel’s First Pure Play Cannabis Firm

BOL Pharma is the Israeli company that announced the first export from the country, with a shipment destined for centers that specialize in the treatment of children with epilepsy and autism in the United Kingdom. The company’s CEO, Dr. Tamir Gedo, stated, “This is truly welcome news and a real breakthrough for the Israeli medical cannabis market. The Israeli cannabis industry has a huge competitive edge in the global arena, compared to many countries trying to enter the cannabis sector… Further opening of the market to exports will enable Israel to become a world leader in the coming years.”

Click Here To Receive Isracann’s Investor Presentation 

The UK legalized medical cannabis in late 2018. Since then, patients have had a hard time getting prescribed treatments in a timely fashion, with most of the supply coming from foreign countries but facing restrictive regulations. As a result, in early March 2020, the UK government announced a change in import restrictions designed to increase the flow of timely medicinal products to registered patients.

This dynamic is common throughout Europe, with countries adopting medical programs without the infrastructure, both regulatory and physical, to provide supply to its own patients. Israel, with its strategic location combined with governmental commitment to the industry, is in prime position to pick up some of the slack.

Isracann Biosciences Inc. (CSE: IPOT) (OTC: ISCNF) is an Israeli-based cannabis company poised to enter both the Israeli domestic and the European export cannabis markets. The company is advancing its fully-funded 230,000 sq ft hybrid greenhouse cultivation project while also advancing a partnership with a late stage project consisting of approximately 200,000 sq ft of greenhouses located on over 880,000 sq ft of agricultural land. In conjunction with the cultivation projects, Isracann is developing European distribution channels while ensuring that all aspects of its business, from cultivation through processing and manufacturing, comply with European Union GMP regulations necessary for international trade. 

While laying the groundwork for an extensive European export operation, the company is certainly not foregoing the burgeoning domestic opportunity in Israel. The country, as of late 2019, had about 46,000 registered patients. Isracann expects this number to roughly double by the end of 2020, by which time the company hopes to be harvesting and distributing products.

The company recently announced a joint venture agreement with two near-term farm operations in the Sharon Plain region of Israel. The IMC-compliant farms operate under preliminary cannabis nursery and cultivation licenses and are preparing to commence planting within weeks with 160,000 sq. ft. of greenhouse canopy on two million sq. ft. of private land. The move paves the way for the company to ramp up sales faster than it expected and could help drive near- and long-term shareholder value.

In a recent two-part interview with CFN Media, Isracann Biosciences CEO Darryl Jones outlined the company’s strategy, assets, and partnerships. He talked about some of the advantages inherent in the Israeli market (ideal climate for cultivation, regulatory environment, advanced research, widespread domestic use, proximity to Europe, etc.). 

Click Here To Receive Isracann’s Investor Presentation 

Click Below to View Video Interview #1: Isracann Biosciences CEO Darryl Jones on Israel as a Cannabis Investment

Click Below to View Video Interview Part #2: Isracann Biosciences CEO Darryl Jones on How Israel became the Cannabis Research Capital of the World

The very first medical cannabis shipment from Israel to the UK marks a new era in the promising Israeli cannabis industry. With the country’s government backing research and development efforts, as well as implementing rules to encourage growth of the industry both domestically and internationally, Israel has cemented its place as a leader for the global cannabis market. The year ahead promises to be pivotal for both the industry in general, and for Isracann Biosciences in particular as the company executes its vision of a comprehensive farm-to-consumer cannabis company. Keep an eye out as the plan unfolds.

Click Here To Receive Isracann’s Investor Presentation

Click Here to Stay Up to Date with CFN Media, Your Premier Destination for Cannabis, CBD &  Psychedelic Financial Media

Isracann Biosciences Contact:

Investor Relations

Toll Free: +1 855.205.0266

CFN Media Contact:

Frank Lane President

[email protected]

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: http://www.cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
Canadian Cannabis Success Being Replayed in Israel Right Now, Featuring an Exclusive Isracann Biosciences CEO Video Interview Part #1 https://mjshareholders.com/canadian-cannabis-success-being-replayed-in-israel-right-now-featuring-an-exclusive-isracann-biosciences-ceo-video-interview-part-1/ Wed, 18 Dec 2019 12:54:06 +0000 https://www.cannabisfn.com/?p=2745327

Ryan Allway

December 18th, 2019

App, Exclusive, News, Top News


After experiencing success with the legalization of cannabis in Canada, Darryl Jones was looking for the next big cannabis opportunity. As it happens, that opportunity was 11,000 miles away from Vancouver in Israel. Fast forward and Jones is now President and CEO of Isracann Biosciences (CSE: IPOT) (OTCPK: ISCNF), Israel’s first pure-play cannabis company to be listed in Canada and the U.S.

“We started looking for other jurisdictions that were similar to Canada four or five years ago and Israel is a prime candidate,” Jones told CFN Media in a recent interview. 

While Israel indeed is following in the footsteps of Canada in many ways, it arguably has the richest history of cannabis research in the world, which provides a nice backstop when it comes to regulations, education and infrastructure. Add in nearly perfect climate for growing cannabis and new cannabis export laws and Isracann setting up headquarters in Israel is one savvy move.

Click Here To Receive Isracann’s Investor Presentation

Jones, whose background is in the capital markets, is looking for his next success after taking cannabis/hemp pet product company True Leaf Medicine public in 2014 at a $10 million valuation and exiting just two years later at a $150 million valuation.

First Crop in June 2020

Isracann is fully funded to construct a 230,000 square-foot facility in Nil, a moshav in southern Israel. The company recently received facility design and land use approvals from the Israeli Land Authority and is soon expecting the final permits for initiate groundbreaking on the first phase of the project.

Phase 1 will include building two 57,500 square-foot hybrid greenhouses and a packing facility with a 6,500 square-foot post-harvesting area, office space and kitchen for employees.

Isracann, which has retained top firms in the Israeli cannabis industry to oversee the design and construction of the cutting edge facility, expects the build to be complete in six months. “We’re roughly timing June 2020 as first crop,” said Jones.

Inexpensive (Really Inexpensive) Production Costs

Once the plants are harvested and dried, they will go on to Isracann’s in-country manufacturing partner to be turned into any number of products for the expanding domestic Israeli market. Israel has one of the highest per capita usage rates of medical cannabis in the world. 

Furthermore, the company intends to capitalize on the fact that Israel this year passed legislation permitting medical marijuana exports, making it only the third country to do so (Canada and Netherlands). Expectations are for the regulatory framework to be in place for exports from Israel to commence in mid-2020.

That’s good timing for Isracann considering when it is expecting its first crops.

Isracann is estimating the cost of production to be just C$0.40-C$0.60 per gram. To give that a little perspective, consider that production costs for cannabis producers in Canada are typically in the range of C$1-C$3 or higher per gram.

Click Here To Receive Isracann’s Investor Presentation

That’s the type of huge opex difference that can give Isracanna the ability to keep strong margins in the domestic market and a competitive advantage when it looks to the future and the  massive European markets that are home to over 750 million people.

Isracann already has a distribution partner for penetrating the European markets when that time comes. The first country on tap is Germany, the largest economy in the E.U. and a burgeoning medical cannabis market.

“Made in Israel”

When it comes to cannabis, Israel is a name recognized globally for its R&D, venerable scientists and agriculture and high quality. To that point, it works as a branding badge for Isracann because distributors and retailers understand that cannabis from Israel is held to a high standard. 

In keeping with those standards, Isracann’s facilities will carry important accreditations, including Israeli Medical Cannabis Good Agricultural Practices (IMC-GAP), Israeli Medical Cannabis Good Security Practices (IMC-GSP) and European Union Good Manufacturing Practices (EU-GMP) certifications.

Speaking to that, Jones said, “[Israel] has 50+ years of cannabis research and they’re really starting to break open the doors on novel products and new formulations; We’re obviously very excited about that.”

Stay tuned for Part 2 of Isracann’s CEO Darrryl Jones exclusive video interview series.

Click Here To Receive Isracann’s Investor Presentation

To learn more about Isracann Biosciences Click Here

Click Here to Receive CFN Media’s Newsletter Every Week in Your Inbox

Disclaimer

CannabisFN.com is not an independent financial investment advisor or broker-dealer. You should always consult with your own independent legal, tax, and/or investment professionals before making any investment decisions. The information provided on https://www.cannabisfn.com(the ‘Site’) is either original financial news or paid advertisements drafted by our in-house team or provided by an affiliate. CannabisFN.com, a financial news media and marketing firm enters into media buys or service agreements with the companies that are the subject of the articles posted on the Site or other editorials for advertising such companies.  We are not an independent news media provider. We make no warranty or representation about the information including its completeness, accuracy, truthfulness or reliability and we disclaim, expressly and implicitly, all warranties of any kind, including whether the Information is complete, accurate, truthful, or reliable. As such, your use of the information is at your own risk. Nor do we undertake any obligation to update the items posted. CannabisFN.com received compensation for producing and presenting high quality and sophisticated content on CannabisFN.com along with financial and corporate news.

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

Ryan Allway

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


]]>
What if Employers had a Convenient Way to Test for Cannabis Use? https://mjshareholders.com/what-if-employers-had-a-convenient-way-to-test-for-cannabis-use/ Fri, 11 Oct 2019 23:00:17 +0000 https://www.cannabisfn.com/?p=2692808

Robin Lefferts

October 11th, 2019

App, Exclusive, News, Top Story


With cannabis legalization sweeping across North America after decades of prohibition, there are some natural concerns surrounding the introduction of the drug to the legal marketplace. In the area of safety, most of the questions have surrounded the issue of impaired driving. One topic that hasn’t gotten a lot of press is that of workplace safety. The most widely-used, current workplace testing solution involves urinalysis, a cumbersome process that is often applied to screen applicants but is not necessarily practical for the detection of recent use on a regular basis.

Cannabix Technologies Inc. (CSE: BLO) (OTC: BLOZF) is actively developing the Cannabix Marijuana Breathalyzer, designed for roadside use by law enforcement officials. The company recently announced the licensing of patent-pending technology, developed by researchers at the University of British Columbia (UBC), that will be focused to offer a cannabis testing solution for workplace and even parental use. Recognizing that the requirements of potential end users vary greatly, Cannabix is looking to offer flexible solutions to meet the needs of a variety of markets.

Workplace Safety and Cannabis

In general, there is still much to be learned from scientific research into cannabis. This is an unsurprising side effect of nearly a century of cannabis prohibition, which greatly limited research on the plant. However, there is growing research that points to workplace issues surrounding cannabis.

A study of postal workers from 1992 showed that employees who tested positive for marijuana in pre-employment screening had significantly more accidents, injuries, and absenteeism compared with those who tested negative. Another study from 2010 pointed to the shortcomings of relying on pre-employment drug screening as a tool to improve workplace safety. Major conclusions included the fact that recent cannabis use (within 4 hours) led to impairment, something that urinalysis screening would not catch. Additionally, urinalysis was not shown to have a meaningful impact on job accident rates.

Parents have their own set of concerns. A 2008 study found that heavy adolescent use of marijuana negatively impacts attention, memory, and learning. A longitudinal study published in 2004 showed a correlation between cannabis use and lower educational attainment. As we have seen with the recent college admissions scandal, there are definitely pressures to do whatever it takes to help children succeed. Being able to conveniently test for marijuana use probably lies at the least invasive, ethically clean end of the spectrum of potential parental actions.

Marijuana Breathalyzer technologies

Cannabix Technologies recognizes the varying needs of the wide range of its potential clients as it develops reliable and portable cannabis testing units. As a first step, the company knows that everyone would prefer a test that doesn’t have to be sent to a lab to analyze results. The breathalyzer model is universally preferred as well, when compared to tests that require the collection of bodily fluids. From that basis, needs start to diverge.

Roadside breathalyzers need to work in all manner of environmental conditions, be rugged and accurate, returning results that will eventually hold up in court. Workplace and parental users will usually be operating in much more controlled environments, and the scrutiny of the results will usually not rise to the level of court proceedings. There is price sensitivity between the markets as well. Employers want to know if someone can safely do their job, and parents want to know if their child has been smoking marijuana before getting behind the wheel of the family car.

Cannabix’s THC Breath Analyzer.

The Cannabix Marijuana Breathalyzer uses field asymmetric waveform ion mobility spectrometry (FAIMS) technology to detect THC from breath samples. FAIMS is an analytical chemistry technology that filters and identifies substances by separating ions. It has the ability to connect directly with Mass Spectrometry technology to confirm its highly sensitive roadside results in the lab, improving the chance that the results stand up in the courts. The THC Breath Analyzer utilizes lower-cost yet highly-effective, versatile, microfluidic sensors that can provide results quickly and cost efficiently.

The Upshot

As with any product company, Cannabix is analyzing the needs of its potential target markets and developing products with features to match those markets. The recent licensing announcement greatly expands the company’s potential client base, and the company expects the resulting THC Breath Analyzer to be available for expanded testing soon, so keep an eye out for further developments as Cannabix Technologies does its part to solve some of the public safety concerns surrounding cannabis use behind the wheel, on the job, and amongst adolescents.

About CFN Media

For Visitors and Viewers 

CFN Media’s Cannabis Financial Network (CannabisFN.com) is the destination for savvy investors and business people profiting from the worldwide cannabis industry. Viewers will see breaking news, exclusive content and original programming involving the people, companies and investments shaping the industry.

For Cannabis Businesses & Companies 

CFN Media is a leading agency and financial media network dedicated to the cannabis industry. We help private, pre-public and public cannabis companies in the US and Canada attract capital, investors and media attention.

Our powerful digital media and distribution platform conveys a company’s message and value proposition directly to accredited and retail investors and national media active in the North American cannabis markets.

Since 2013, CFN Media has enabled the world’s preeminent cannabis companies to thrive in the capital and public markets.

Avatar

About Robin Lefferts


]]>